Similar articles

• [2-year experiences with a combination treatment of Parkinsonism with L-dopa and a decarboxylase inhibitor (Benserazid, Ro 4-4602)].

  Birkmayer W, Linauer W, Mentasti M, Riederer P. Birkmayer W, et al. Wien Med Wochenschr. 1974 Jun 1;124(22):340-4. Wien Med Wochenschr. 1974. PMID: 4275492 Clinical Trial. German. No abstract available.
• [Treatment of Parkinson's syndrome with L-dopa and its methylated derivatives: 3-OMD and 4-OMD associated with a decarboxylase inhibitor. Clinical and biochemical study].

  Tissot R, Bartholini G, Constantinidis J, Eisenring JJ, Geissbühler F, Yanniotis G, de Ajuriaguerra J. Tissot R, et al. Schweiz Med Wochenschr. 1973 Oct 20;103(42):1466-74. Schweiz Med Wochenschr. 1973. PMID: 4750149 French. No abstract available.
• [Quantitative rigor determination in Parkinson's disease. Myo-integration for therapy control of L-Dopa in combination with a decarboxylase inhibitor (Ro 8-0576)].

  Gehlen W, Eisenlohr JJ. Gehlen W, et al. Nervenarzt. 1974 Jan;45(2):22-9. Nervenarzt. 1974. PMID: 4601993 German. No abstract available.
• [Decarboxylase inhibitor given in combination with l-dopa. A new therapeutic principal in parkinsonism].

  Dietrichson P. Dietrichson P. Tidsskr Nor Laegeforen. 1973 Oct 10;93(28):2113-5. Tidsskr Nor Laegeforen. 1973. PMID: 4590070 Review. Norwegian. No abstract available.
• [Therapy of Parkinsonian syndrome using L-dopa. Current state and problems].

  Fischer PA. Fischer PA. Nervenarzt. 1974 Dec;45(12):617-27. Nervenarzt. 1974. PMID: 4614096 Review. German. No abstract available.